Our Mission
We aim to cure disease by reprogramming immunity using physiologic dendritic cells. We exploit immunology to deliver vaccination in a more targeted manner with implications for both efficacy and safety. Our cells have the potential to drive immunity against specific viral or cancer targets or precisely dampen harmful immune activation in the case of autoimmunity or graft vs host disease.
Our Timeline
-
Unexpected clinical resultsEdelson reports first cases of successful treatment of cutaneous T cell lymphoma (CTCL) patients using ECP. New England Journal of Medicine Vol.316 (6) 1987.READ MORE -
ECP Regulatory ApprovalFDA grants J&J Therakos approval for use of ECP to treat CTCLREAD MORE -
Wider clinical use of ECPPublication of use of ECP in management of cardiac transplant Rejection. New England Journal of Medicine Vol. 339 (24) 1998.READ MORE
-
ECP - a dendritic cell therapyPublication of role of dendritic cell priming as key to ECP mechanism. Blood 2010 Vol. 116 (23)READ MORE
-
Transimmune foundedTransimmune AG incorporated and raises $5m seed investment from QureInvest Fund. Foundational patents filed.
-
ECP market leader aquiredMallinckrodt acquires ECP market leader Therakos for $1.3bn.
-
Endorsement by ECP cliniciansAmerican Council for ECP Consensus paper endorses Transimmune’s science. J Clin Apher Vol. 33(4) 2018.READ MORE
-
Endorsement by ECP Market LeaderMallinckrodt strikes research collaboration with Transimmune.
-
Building cell therapy platformInitiated research program with Emory University and the Bill and Melinda Gates Foundation
-
Major Grant AwardAward of inaugural ARPA-H grant with Emory, Yale and University of GeorgiaREAD MORE
About Us
Our breakthrough science has its roots in serendipity. Our founder Dr Richard Edelson sought to understand the extraordinary and unexpected clinical outcomes seen in extracorporeal photopheresis, an early cell therapy he invented in the 1980s. In doing so he uncovered how to replicate ex vivo the conditions needed to prime dendritic cells naturally. A major departure from the highly artificial methods used historically.
Our Science
By putting physiology at the heart of manufacturing our cellular product, two benefits potentially arise that can revolutionize the clinical performance of dendritic cell therapies:
In vivo potency is enhanced by enabling a truly physiologic partnership with the broader immune network.
Cost of goods and the treatment pathway are radically improved by enabling point of care products to be generated in hours.
News & Publications
